Abstract Previous studies from our laboratory identified a number of miRNAs that were aberrantly expressed in colorectal cancer (CRC) tissue. However, their diagnostic and prognostic value in serum has not been fully evaluated. In the present study, we measured the levels of five miRNAs (miR-21, miR-31, miR-92a, miR-18a, and miR-106a) in serum samples from 200 CRC patients, 50 advanced adenoma patients, and 80 healthy controls by real-time quantitative polymerase chain reaction (RT-PCR). In our study, the levels of miR-21 and miR-92a in patients with CRC and advanced adenoma were significantly higher than those in healthy controls (all P<0.05). MiR-21 yielded an area under the receiver-operating characteristics (ROC) curve (AUC) of 0.802 and miR-92a yielded an AUC of 0.786 in discriminating CRCs from the controls. Additionally, miR-21 and miR-92a yielded an AUC of 0.709 and 0.701, respectively, in discriminating advanced adenomas from the controls. Combined ROC analyses using both miRNAs, revealed an elevated AUC of 0.847 in discriminating CRCs, and an AUC of 0.722 in discriminating advanced adenomas from the controls. In the multivariate Cox proportional hazards analysis, high miR-92a expression in CRC was independently associated with poor survival (P=0.03; hazard ratio 4.36; 95 % confidence interval=1. 64-11.57). No significant difference was observed in the levels of miR-18a, miR-31, and miR-106a among CRC, advanced adenoma, and control samples. In summary, our data indicate that miR-21 and miR-92a serum levels have potential value for early detection of CRC. Furthermore, miR-92a has prognostic value in CRC patients.
Introduction
Colorectal cancer (CRC) is a major cause of cancer-related death worldwide [1] , and the incidence and mortality of CRC in China have increased rapidly in the past decades [2] . Most CRC-related deaths can be prevented through early diagnosis and surgical removal of early-stage cancer and precancerous lesions. Advanced adenoma, which is an adenoma with significant villous features, a size of 1.0 cm or more and highgrade dysplasia, bridges benign and malignant states in colorectal tumorigenesis and represents the optimal target lesion for CRC prevention strategies [3] . Several CRC screening tests, including fecal occult-blood test and colonoscopy, are frequently used in the detection of CRC. Nevertheless, none of these tests have been established as well-accepted screening tools due to their invasiveness, high cost, or low sensitivity [4] . Thus, there is an urgent need for new noninvasive biomarkers to improve the detection of CRC. In addition, there is a need to identify new, noninvasive prognostic biomarkers for CRC in order to improve postoperative treatment strategies.
MicroRNAs (miRNAs) are small, non-coding RNAs that regulate the translation of specific protein coding genes. Recent studies have revealed the role of miRNAs in a variety of basic biological and pathological processes [5] , and the association of miRNA signatures with human diseases has been established [6, 7] . In 2008, Lawrie et al. [8] first established the existence of miRNAs in circulation. Soon after, circulating miRNAs have been proposed as sensitive and informative biomarkers in the diagnosis and prognosis of several types of cancer [9] [10] [11] [12] . Previous studies from our laboratory identified a number of miRNAs that were aberrantly expressed in CRC tissue [13, 14] ; however, their diagnostic and prognostic values in serum have not been fully evaluated to date.
In this study, we investigate five miRNAs (miR-21, miR-31, miR-92a, miR-18a, and miR-106a) based on the results obtained from our previous studies [13, 14] and their reported relevance to CRC [15] . We examined their expression in serum samples from 200 CRC patients, 50 advanced adenoma patients, and 80 healthy volunteers by real-time quantitative polymerase chain reaction (RT-PCR). Furthermore, we investigated the feasibility of using these miRNAs as potential diagnostic and prognostic CRC biomarkers.
Materials and methods

Study cohort
Following ethical approval and written informed consent, whole blood samples were collected from 200 CRC patients, 50 advanced adenoma patients, and 80 healthy age-matched volunteers, which served as controls. All patients were diagnosed and treated at the West China Hospital in Chengdu, China from November 2006 to June 2008. The patient group was representative of the general distribution of patients from the West China Hospital. All blood samples were collected 1 day before surgery, and all advanced adenomas and CRCs were pathologically confirmed. Patients were excluded if they had any of the following issues: clinical diagnosis of familial adenomatous polyposis or hereditary nonpolyposis CRC, diagnosis of other types of cancer at any site at the time of selection, undergoing chemotherapy or radiotherapy before blood sampling, and received a blood transfusion in the past 3 months. Information regarding the patients' gender, age, tumor location, size, pTNM stage, differentiation, serum carcinoembryonic antigen (CEA), hepatitis B virus (HBV) status, and cigarette smoking status was obtained from the hospital surgical and pathological records. Tumors were staged according to the UICC tumor-node-metastasis (TNM) staging system. The control blood samples were collected from healthy volunteers who do not have a current or previous malignancy, or inflammatory condition. Clinicopathological features of patients are summarized in Supplementary Table 1 .
Follow-up
Follow-up of the patients was performed by a combination of outpatient visits, letters, and telephone calls. Patients were asked to perform physical examinations, blood tests, chest radiography, and liver ultrasonography every 3-6 months, and colonoscopy annually. Computed tomography or magnetic resonance imaging was performed when required. For the present analysis, the follow-up data were updated in April 2011. The mean time of follow-up was 36.4 months (range, 4-53 months).
Sample processing and total RNA extraction Up to 4 ml of whole blood from each participant was collected in a serum separator tube containing EDTA. Samples were left to clot at room temperature for 30 min and then were centrifuged at 4,000 rpm for 10 min at 4°C. Serum was removed, aliquoted, and stored at −80°C until further use. Total RNA was extracted from 500 μl of serum using the standard TRIZOL LS (Invitrogen, CA, USA) method according to the manufacturer's protocol. Total RNA concentration and integrity were determined with an ultraviolet specrophotometer (Beckman, CA, USA) and a digital gel image analysis system (Bio-Rad, CA, USA). The median storage time between blood sample processing for serum and endpoint analysis was 32 months.
Selection of serum miRNA markers
A panel of five cancer-associated miRNAs (miR-21, miR-31, miR-92a, miR-18a, and miR-106a) was chosen based on the results from our previous studies [13, 14] and their reported relevance to CRC [15] . MiR-16 was selected as an internal control [9, 16] .
MiRNA quantification by real-time quantitative RT-PCR
Total RNA samples were reverse transcribed (RT) to generate specific cDNAs using primers specific to each miRNA target. Specific cDNAs were then amplified by real-time quantitative RT-PCR using TaqMan miRNA primers and probes purchased from Invitrogen. The sequences of primers and probes are summarized in Supplementary  Table 2 . The protocol used was designed and validated by the others at our laboratory [13, 14] . Briefly, total RNA from 500 μl of serum was reverse transcribed with a miRNA RT reaction system, and the PCRs were carried out in a final volume of 30 μl using an iCycer iQ System (Bio-Rad). All the reactions, including a notemplate control, were run in triplicate. The relative expression of each miRNA was normalized to miR-16 and calculated with the 2 −ΔΔCT method [17] .
Statistical analysis
MiRNA expression levels were compared using the MannWhitney U test or Kruskal-Wallis test. Receiver-operating characteristics (ROC) curves were established to evaluate the diagnostic value of serum miRNAs for differentiating tumors from controls. The overall survival was analyzed by log-rank test, and survival curves were plotted according to Kaplan-Meier. Univariate Cox regression was performed on each clinical covariate to examine its influence on patient survival. Final multivariate models were based on step-wise addition. A Wald statistic of P <0.05 was used as the criterion for inclusion in final multivariate models. Data were presented as mean ± SD. All tests were two tailed and results with P<0.05 were considered statistically significant. All statistical analyses were performed with SPSS 17.0 software.
Results
Expression of miRNAs in serum samples from patients and healthy controls
Expression of the five miRNAs was detectable in all analyzed samples. There were no significant differences in serum miRNA levels with respect to gender and age among CRC patients, advanced adenoma patients, and healthy controls (P=0.114, χ2 test; P=0.934, ANOVA). MiR-16 expression in the three groups was not significantly different (P=0.381), and was therefore used to normalize the RT-PCR data.
To identify the miRNAs that were upregulated in serum, we first examined the levels of five target miRNAs in CRC, advanced adenoma, and control samples. Although the miRNAs were previously identified to be relatively abundant in CRC tissues, our results showed that serum miRNA signatures were not fully consistent with that of solid tumors. No significant difference was observed in the levels of miR-18a, miR-31, and miR-106a among CRC, advanced adenoma, and control samples (P= 0.093 for miR-18a, P= 0.190 for miR-31, and P= 0.214 for miR-106a). Thus, these three miRNAs were not included in further analyses. The expression of the remaining two miRNAs, miR-21 and miR-92a, was significantly elevated in CRC and advanced adenoma samples when compared with controls (all P < 0.05, Fig. 1 ).
Relationship between serum miRNA expression and clinicopathological features In addition to examining the expression of miRNAs in serum, the relationship between miR-92a and miR-21 expression and clinicopathological features of patients was examined. The results showed that high miR-92a expression was associated with advanced pTNM stage (P<0.001) and positive nodal status (P=0.001). In addition, high miR-21 expression was associated with advanced pTNM stage (P=0.045) and poor differentiation (P<0.001). There were no significant associations between miRNAs and gender, age, tumor location, tumor size, CEA, HBV status, or cigarette smoking (all P > 0.05, data not shown).
Expression of miRNAs in serum samples from patients in relation to diagnosis Since miR-21 and miR-92a levels were significantly elevated in the serum of CRC patients when compared to healthy controls, ROC curve analysis was used to explore the potential of using circulating miRNAs as biomarkers for CRC. These analyses revealed that serum levels of both miR-21 and miR-92a were potential biomarkers for differentiating CRC patients from controls and had under the ROC curve (AUC) of 0.802 [95 % confidence interval (CI) = 0.752-0.852] and 0.786 (95 % CI=0.728-0.845), respectively (Fig. 2a, b) . At a cut-off value of 0.0043 for miR-21, the sensitivity was 65 % and the specificity was 85 %. At a cut-off value of 0.00017 for miR-92, the sensitivity was 65.5 % and the specificity was 82.5 %. Combined ROC analyses resulted in an AUC of 0.847 (95 % CI = 0.803-0.891) with a 68.0 % sensitivity and 91.2 % specificity (Fig. 2e) .
Since the expression of miRNAs in the serum of patients with advanced adenomas was higher than in healthy controls, we further investigated the diagnostic value of serum miR-21 and miR-92a expression levels in the detection of early lesions in CRC development. ROC curve analyses revealed that both miRNAs might be helpful in differentiating adenomas from controls. The AUC for miR-21 was 0.709 (95 % CI = 0.618- Fig. 1 Serum levels of miR-21 (a) and miR-92a (b) from CRC patients, advanced adenoma patients, and healthy controls. The lines inside the boxes denote the medians. Expression levels of the miRNAs are normalized to miR-16 Fig. 2 Receiver-operating characteristics (ROC) curve analysis using serum miR-21 and miR-92a for discriminating CRCs from healthy controls. a ROC curve for miR-21 in discriminating CRCs. b ROC curve for miR-92a in discriminating CRCs. c ROC curve for miR-21 in discriminating adenomas. d ROC curve for miR-92a in discriminating adenomas. e Combined ROC curve for miR-21 and miR-92a in discriminating CRCs. f Combined ROC curve for miR-21 and miR-92a in discriminating adenomas 0.801) and 0.901 for miR-92a (95 % CI=0.610-0.792) (Fig. 2c, d ). Combined ROC analyses resulted in an AUC value of 0.722 (95 % CI=0.633-0.811) with a sensitivity of 70.0 % and specificity of 70.0 % (Fig. 2f) .
Expression of miRNAs in serum samples from patients in relation to prognosis Follow-up data were available for the 166/200 (83 %) CRC patients included in this study. During the follow-up period, 38/166 (23 %) patients died of CRC. Patients with high serum miR-92a expression had a significantly worse prognosis than patients with low expression, with a 3-year overall survival of 52.2 and 93.8 %, respectively (P<0.001, Fig. 3 ). There was no statistically significant association between miR-21 expression and prognosis (P=0.126).
A Cox proportional hazards analysis was used to further evaluate the potential of serum miR-92a expression as a prognostic biomarker. Univariate survival analyses indicated that miR-92a expression, pTNM stage, differentiation, and tumor size were associated with prognosis, while miR-21 expression, gender, age, tumor location, CEA, HBV status, and cigarette smoking were not associated with prognosis. In the multivariate Cox proportional hazards analysis, which included miR-92a, pTNM stage, differentiation, and tumor size, high miR-92a expression was independently associated with poor survival (P=0.03; HR=4.36; 95 % CI=1.64 -11.57; Table 1 ).
Discussion
CRC is one of the leading causes of cancer death worldwide. Although there has been great progress in the diagnosis and prognosis of CRC in the past decades, there is still a need to improve early detection screening methods and to identify new prognostic biomarkers [1, 2] . Ideal biomarkers should be easy to measure and have a strong association with clinical outcome. miRNAs could match these proposed criteria [9] [10] [11] [12] .
In the present study, miR-21 and miR-92a serum levels in patients with CRC and advanced adenoma were significantly higher than those detected in healthy controls. Both miR-21 and miR-92a could be potential biomarkers for CRC and yielded an AUC of 0.802 and 0.786, respectively. Combined ROC analyses revealed an AUC of 0.847, indicating the additive effect in the diagnostic value of both miRNAs. Furthermore, both miRNAs were helpful in differentiating advanced adenomas from healthy controls, with an AUC of 0.709 for miR-21 and 0.701 for miR-92a. Combined ROC analyses revealed an AUC value of 0.722, suggesting their potential value for early detection of CRC. In the multivariate Cox proportional analysis, high miR-92a expression was associated with poor survival in CRC patients, independent of tumor staging and differentiation.
MiR-92a is part of the miR-17-92 gene cluster located at chromosome 13q13. As a known oncomir, the miR-17-92 cluster can promote cell proliferation, suppress apoptosis of cancer cells, induce tumor angiogenesis and accelerate tumor progression [18] . Elevated expression of miR-92a has been observed in CRC [10, 12] , lung cancer [19] , and thyroid cancer [20] , suggesting an important role in tumorigenesis. Ng et al. [12] reported that circulating miR-92 was a potential biomarker for CRC diagnosis, which is consistent with our data. Furthermore, our results showed that miR-92a had a prognostic potential, and high miR92a expression in CRC patients was associated with poor survival. However, contrary results were reported in other diseases. For instance, Tanaka et al. [21] showed that miR-92a was dramatically decreased in the plasma of acute leukemia patients. They used miR-638 as an internal control. Shigoka et al. [22] demonstrated that the amount of miR-92a in plasma from hepatocellular carcinoma patients was decreased compared with that of healthy donors. These inconsistencies may be due to the different diseases and methods used in different studies.
MiR-21 is expressed at high levels in most solid tumors [23] . Studies in human cell lines showed that miR-21 could target tumor suppressor genes, such as PTEN [24] and TPM1 [25] . Our results showed that serum miR-21 had a diagnostic potential for CRC (AUC = 0.802). We found that miR-21 was also a potential diagnostic biomarker (AUC= 0.709) for advanced adenoma. However, although an association of high miR-21 expression in CRC tissue with poor survival was observed by Schetter et al. [6] , our results indicated that serum miR-21 expression was not associated with patient survival. These differences may be due to [12] demonstrated that miR-21 expression in plasma from CRC patients was lower than in healthy controls, which is also inconsistent with our current findings. Nevertheless, the results of Ng et al. have to be taken with caution because their study included only five samples.
MiR-18a and miR-106a also belong to the miR-17-92 cluster [18] , while miR-31 is located at chromosome 9p21.3 [26] . These miRNAs are expressed at high levels in CRC tissue [12, 14] . CRC patients with high miR-18a expression tended to have a poorer prognosis than the low expression group [15] . High miR-31 expression in CRC tumor tissue was related to advanced pTNM stage [14] . In our study, no significant difference was observed in serum miR-18a, miR-31, and miR-106a levels among the CRC patients, advanced adenomas patients, and healthy controls. Our results differ from those of other studies; however, this difference may be attributed to the different samples (solid tissue versus serum) and methods used.
It has been established that the expression of several miRNAs, including the miR-17-92 cluster [27] , miR-31 [28] , and miR-106a [29] , changes in HBV carriers and/or cigarette smokers. China has the largest population of HBV carriers [30] and cigarette smokers [31] in the world. In our study, we examined the possible association of miR-21 and miR-92a expression with HBV status and cigarette smoking in CRC patients; however, no association was observed. A possible reason is that the expression of these miRNAs in CRC patients is more influenced by mechanisms involved in tumorigenesis than by HBV infection or cigarette smoking.
One possible concern in this and similar studies of circulating miRNA is the lack of consensus about internal controls for quantitative RT-PCR. Several internal controls have been used in different tumor types, such as miR-16 [9] , miR-197 [32] , 5S RNA [14] , and RNU6B [12] . The results of this study showed that miR-16 expression in serum was similar across the patient and control groups, and therefore could be used as a reliable internal control in CRC miRNA expression studies. Secondly, all the patients were from the Southwestern part of China and most of the patients were relatively poor with high turnover due to work that led to the lack of standard postoperative therapy, regular examination, and high-rate follow-up. Therefore, we were not able to collect enough data to analyze disease-free survival and therapy response in relation to the miRNAs.
In conclusion, miR-21 and miR-92a have potential as noninvasive biomarkers for the early detection of CRC. Furthermore, high miR-92a expression is independently associated with poor survival in CRC patients and may be used in the future as a potential prognostic biomarker.
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